Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhong Ji Longevity Science Group's EBITDA for the
six
months ended in Dec. 2025 was HK$-1.6 Mil.
Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-12.5 Mil.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Zhong Ji Longevity Science Group was 73.60% per year. The lowest was -200.60% per year. And the median was 13.50% per year.
Zhong Ji Longevity Science Group's EBITDA per Share for the
six
months ended in Dec. 2025 was HK$-0.00.
Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.
During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Zhong Ji Longevity Science Group was 90.80% per year. The lowest was -122.30% per year. And the median was -26.90% per year.
Zhong Ji Longevity Science Group (HKSE:00767) EBITDA Explanation
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.
Zhong Ji Longevity Science Group EBITDA Related Terms
Zhong Ji Longevity Science Group EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Zhong Ji Longevity Science Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhong Ji Longevity Science Group EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Zhong Ji Longevity Science Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zhong Ji Longevity Science Group's EV-to-EBITDA falls into.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zhong Ji Longevity Science Group's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Zhong Ji Longevity Science Group's EBITDA was HK$-6.4 Mil.
Zhong Ji Longevity Science Group's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, Zhong Ji Longevity Science Group's EBITDA was HK$-1.6 Mil.
EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-12.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.
Zhong Ji Longevity Science Group (HKSE:00767) has a EBITDA of HK$-12.5 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Zhong Ji Longevity Science Group.
Is Zhong Ji Longevity Science Group's EBITDA too high?
Zhong Ji Longevity Science Group's current EBITDA is HK$-12.5 Mil. Overall, Zhong Ji Longevity Science Group has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhong Ji Longevity Science Group's EBITDA compare to TMO and DHR?
Zhong Ji Longevity Science Group's EBITDA of HK$-12.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Diagnostics & Research company?
A good EBITDA depends on the Medical Diagnostics & Research industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Zhong Ji Longevity Science Group. Zhong Ji Longevity Science Group's current EBITDA is HK$-12.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhong Ji Longevity Science Group stock overvalued right now?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group (HKSE:00767) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.89, compared to a current price of HK$0.36 — trading 59.6% below its estimated fair value. The current EBITDA is HK$-12.5 Mil. Zhong Ji Longevity Science Group's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Zhong Ji Longevity Science Group (HKSE:00767), the current EBITDA is HK$-12.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhong Ji Longevity Science Group (HKSE:00767) Overvalued in 2026?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group stock appears to be undervalued.
The current stock price of HK$0.36 is trading 59.6% below its estimated GF Value™ of HK$0.89.
GuruFocus considers Zhong Ji Longevity Science Group to be Possible Value Trap.
Key valuation signals for HKSE:00767:
EBITDA: HK$-12.5 Mil
GF Value™: HK$0.89 vs. price of HK$0.36 (59.6% below fair value)
No single metric tells the full story. See the HKSE:00767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhong Ji Longevity Science Group Ltd is an investment holding company. Through its subsidiaries, it engages in Longevity science business, Money lending and Financial Advisory, Securities and other investments, and Property investment. The company generates the majority of its revenue from the Longevity Science business. The Longevity science business includes the provision of diagnostic consultation, health and medical testing and checking, distribution of cancer prevention & immunity healthcare supplements, and the sales and distribution of longevity wine.
55GF Score
Get the complete analysis for HKSE:00767
EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00767 has been successfully added to your 
